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Liver cirrhosis is associated with severe hemodynamic changes which include hyperdy-
namic circulation with increased cardiac output, heart rate and reduced systemic vascular
resistance. The term cirrhotic cardiomyopathy is deﬁned as the presence of chronic cardiac
dysfunction, characterized by blunted contractile responsiveness to stress and altered
diastolic relaxation with electrophysiological abnormalities (QT interval prolongation), all
occurring in the absence of any other cardiac disease. The key role in diagnosis is played by
2-dimensional echocardiography, electrocardiography and various serum markers
(natriuretic peptides). The prognosis of the patients with cirrhotic cardiomyopathy is
affected by heart failure, which can develop during invasive procedures (surgery, insertion
of a transjugular intrahepatic portosystemic shunting and liver transplantation). No
accepted speciﬁc treatment of cirrhotic cardiomyopathy exists. The therapy should follow
the recommendations for the treatment of liver cirrhosis and heart failure.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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In 1953 Kowalski and Abelman observed the elevation of the
resting cardiac output, increased stroke volume, normal blood
pressure and low systemic vascular resistance in patients with a
history of alcoholism, inadequate diet, and liver cirrhosis [1].
Later unexpected deaths due to heart failure were reported in the
patients following liver transplantation, transjugular intrahepatic
portosystemic shunts (TIPS) insertion, and surgical portocaval
shunts [2]. These facts increased interest in study of the
myocardial dysfunction in patients with liver cirrhosis. Now, it
is clear that similar changes can develop also in patients with
non-alcoholic liver cirrhosis. The studies showed that liver
cirrhosis per se is associated with signiﬁcant cardiovascular
abnormalities [3,4]. It became clear that liver cirrhosis is asso-
ciated with increased resting cardiac output (CO), decreased
systemic vascular resistance (SVR), reduced myocardial contrac-
tility or systolic incompetence, especially under the stress con-
ditions, increased left ventricular thickness associated with
diastolic dysfunction and ecg abnormalities (QTc interval pro-
longation) [5]. These abnormalities are formally described as
“cirrhotic cardiomyopathy (CCM),” which is deﬁned as chronic
cardiac dysfunction in patients with liver cirrhosis. It is char-
acterized by blunted contractile responsiveness to stress and/or
altered diastolic relaxation with electrophysiological abnormal-
ities, in the absence of known cardiac disease and irrespective of
the cause of cirrhosis [6,7].
These patients can present with dyspnea, ﬂuid retention
and limited exercise capacity. Now there is evidence that
impaired liver function and portal hypertension with
splanchnic vasodilatation lead to the development of the
hyperdynamic syndrome. This review discusses the possible
pathogenic mechanisms, clinical presentation and potential
treatment of cirrhotic cardiomyopathy.
2. Pathophysiology
Impaired liver function and portal hypertension with
splanchnic and systemic vasodilatation led to development
of hyperdynamic syndrome, which is characterized with
increased cardiac output, heart rate, decreased peripheral
systemic resistance and normal or decreased arterial pressure.
Furthermore, other factorsmay play an important role: increased
sympathetic nervous activity, increased blood volume and the
presence of arteriovenous communications [8,9]. This further
aggravates the hyperdynamic circulation and can progress into
impaired myocardial contractility with electrophysiological
abnormalities called cirrhotic cardiomyopathy.
2.1. Systemic vascular resistance
In patients with liver cirrhosis, the SVR is reduced as
a complex result of the presence of arteriovenouscommunications, increased level of circulating vasodilators,
reduced resistance to vasoconstrictors and increased sensi-
tivity to vasodilators. Increased level of circulating vasodila-
tors is augmented by vasodilators escaping degradation in
the diseased liver or their bypassing through portosystemic
collaterals [10]. The recent studies show the important role of
nitric oxide, carbon monoxide, endogenous cannabinoids,
brain natriuretic peptide, calcitonin gene-related peptide,
and endothelin-3 as potent vasodilators in patients with liver
cirrhosis [7,11,12]. Furthermore, vascular endothelial growth
factor (VEGF) seems to stimulate angiogenesis and the devel-
opment of portosystemic collaterals [13].
2.2. Volume expansion
In patients with liver cirrhosis, blood and plasma volumes are
increased, but the distribution between central and periph-
eral vascular areas is unequal [10,14]. Central and arterial
blood volumes (i.e. blood volume in the heart, lungs and
central arterial tree) are decreased compared to non-central
blood volume (splanchnic). This redistribution results in
central (effective) hypovolemia. Low effective blood volume
in combination with arterial hypotension leads to volume
and baroreceptor activation of potent vasoconstriction sys-
tems such as sympathetic nervous system and renin angio-
tensin aldosterone system [15,16]. This can result in further
water retention and further redistribution.
2.3. Myocardial dysfunction
It has been shown that left ventricular systolic function is
normal or even increased at rest, but after stress, exercise or
other stimuli it becomes impaired [2–4]. Furthermore, other
studies showed a decreased myocardial response with ino-
tropic and chronotropic incompetence after exercise-induced
or pharmacologic increase in afterload or heart rate [6]. All
these ﬁndings were reported in patients with alcoholic and
non-alcoholic cirrhosis.
Diastolic dysfunction is relatively frequent in patients
with liver cirrhosis and is associated with increased mortality
[17–19]. The recent studies of left ventricular ﬁlling in cirrho-
sis support the presence of a subclinical myocardial disease
with diastolic dysfunction [13,20]. It has been shown that
myocardial ﬁbrosis and increased myocardial mass lead to
increased stiffness of the myocardial wall resulting in
impaired ventricular ﬁlling and diastolic dysfunction.
Therefore, early diagnosis of diastolic heart failure could
help to identify risk patients [21].
2.4. Heart pressures
Initial phases of liver cirrhosis are associated with upper
normal values of right ventricular pressure, right atrial
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wedge pressure. Actual values of these parameters depend on
the degree of the volume status: ﬂuid retention with forma-
tion of ascites may result in increase of right atrial pressure;
paracenthesis with removal of ascetic ﬂuid and diuretic
treatment may decrease these parameters. It has been
shown, that physical exercise, pharmacological stress, and
therapeutic procedures may affect cardiac pressures (the left
ventricular end diastolic pressure increases but the cardiac
stroke index and left ventricular ejection fraction fall during
exercise, which indicates an abnormal ventricular response
to an increase in ventricular ﬁlling pressure) [6–10]. Reduced
left ventricle afterload (due to decrease of systemic vascular
resistance) may mask left ventricle failure for a long time.
But, in late stages of cirrhotic cardiomyopathy, the heart is
not able to compensate for all volume changes. In these
patients cardiac output decreases and left ventricle ﬁlling
pressure increases. This is a sign of poor prognosis.
2.5. Pulmonary circulation
Hemodynamic studies in patients with liver cirrhosis showed
signiﬁcant changes of pulmonary circulation. There are two
different entities in patients with liver cirrhosis: portopul-
monary hypertension and hepatopulmonary syndrome. Por-
topulmonary hypertension is characterized with increased
mean pulmonary artery pressure and pulmonary vascular
resistance in the presence of portal hypertension. The key
factors in development of portopulmonary hypertension are
abnormal vasoconstriction and obliterative remodeling of
lung circulation. In clinical studies, 2–10% of cirrhotic patients
have been estimated to be at risk of developing pulmonary
hypertension. Portopulmonary hypertension seems to be a
signiﬁcant prognostic factor in patients with liver cirrhosis
[22].
Hepatopulmonary syndrome (HPS) is characterized by intra-
pulmonary vasodilatation (increased production and decreased
elimination of vasodilators), the presence of intrapulmonalTable 1 Proposed Diagnostic Criteria for Cirrhotic Cardiomyopa
A working deﬁnition of cirrhotic cardiomyopathy
 A cardiac dysfunction in patients with cirrhosis characterized by imp
relaxation with electrophysiological abnormalities in the absence of oth
Systolic dysfunction
 Blunted increase in cardiac output with exercise, volume challenge o
 Resting EFo55%
Diastolic dysfunction
 E/A ratio o1.0 (age-corrected)
 Prolonged deceleration time (4200 ms)
 Prolonged isovolumetric relaxation time (480 ms)
Supportive criteria
 Electrophysiological abnormalities
 Abnormal chronotropic response
 Electromechanical uncoupling/dyssynchrony
 Prolonged QTc interval
 Enlarged left atrium
 Increased myocardial mass
 Increased BNP and pro-BNP
 Increased troponinarterio-venous shunts and development of ventilation/perfusion
mismatch. The reported frequency of hepatopulmonary syn-
drome in patients with liver disease is between 4% and 29%
[7,9,22]. The main clinical features of HPS are hypoxemia,
othodeoxia and plathypnea.
2.6. Electrophysiological changes
In patients with liver cirrhosis, multiple electrophysiological
abnormalities have been recognized. They include QT-interval
prolongation, electrical and mechanical dyssynchrony and
chronotropic incompetence. Prolongation of QT-interval is
attributed to delayed repolarization of cardiomyocytes due to
K channel abnormalities and sympatoadrenergic hyperactivity
[23,24]. The defect in electromechanical coupling leading to
dyssynchrony between electrical and mechanical systoles was
proven by Bernardi et al. [23]. and Henriksen et al. [25] They
reported signiﬁcant prolongation of pre-ejection time, and the
difference between electrical and mechanical systole was
evaluated using catheterization curves.
Chronotropic incompetence deﬁned as the failure of the
heart rate to respond to physiological and pharmacological
stimuli was observed by both alcoholic and nonalcoholic
patients and is proportional to the severity of cirrhosis.3. Diagnostic criteria for cirrhotic
cardiomyopathy
A working deﬁnition was proposed in the World Congress of
Gastroenterology in Montreal (Canada) in 2005 and is detailed
in Table 1.
3.1. Serum markers
Cirrhotic cardiomyopathy is associated with increased pro-
duction of natriuretic peptides. Brain natriuretic peptide
(BNP) emerged as a sensitive marker of left ventricularthy. Adopted from Figueiredo et al. [26].
aired contractile responsiveness to stress and/or altered diastolic
er known cardiac disease
r pharmacological stimuli
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[27] and Wong et al. [28] showed that liver cirrhosis is
associated with increased production of BNP in ascitic and
preascitic phase. Plasma BNP and NT-proBNP level is asso-
ciated with the severity of the cirrhosis and with the degree
of cardiac dysfunction [29]. Cirrhotic cardiomyopathy is fre-
quently associated with increased troponin level [30]. Liver
cirrhosis and cardiac dysfunction is also associated with the
increase of other markers, such as adrenomedullin, glycogen
phosphorylase BB and heart fatty acid binding proteins
[31,32]. It has been shown that the levels of these markers
of cardiac dysfunction are generally higher in ascitic than
nonascitic cirrhotic patients. The assessment of serum mar-
kers could be helpful in risk stratiﬁcation and therapy
monitoring in patients with liver cirrhosis [32].
3.2. Transjugular intrahepatic portosystemic shunt
A transjugular intrahepatic portosystemic shunt (TIPS) is a
percutaneous created connection within the liver between
the portal and systemic circulation. A TIPS is placed to reduce
portal pressure in patients with severe complications of
portal hypertension (variceal bleeding, refractory ascites and
hepatorenal syndrome) [33,34]. However, TIPS placement can
be associated with potential complications and negative side
effects [35]. TIPS placement is associated with increased heart
rate, cardiac output and plasma volume, and reduced sys-
temic vascular resistance and arterial blood pressure [36].
Furthermore, liver cirrhosis per se is frequently associated
with cardiac dysfunction and abnormalities in the central,
splanchnic and peripheral circulation, and hemodynamic
changes caused by humoral and nervous dysregulation [7,37].
Transjugular intrahepatic portosystemic shunt (TIPS)
insertion represents a stressful situation in this group of
patients. Thus, the prognosis of the patients after TIPS
procedure can be affected by the development of heart fail-
ure, especially in those who have preexisting myocardial
dysfunction. Therefore, early diagnosis of dysfunction of the
myocardium is essential not only before, but also after the
TIPS procedure. In our study, we evaluated the use of
echocardiography for monitoring of the hemodynamic
changes in the group of 55 patients with liver cirrhosis [38].
We have found that liver cirrhosis is frequently associated
with diastolic dysfunction; transjugular portosystemic shunt
creation is associated with signiﬁcant hemodynamic
changes. These changes can be monitored using echocardio-
graphy. Our study conﬁrmed the need of hemodynamic
monitoring of patients undergoing TIPS procedures and
showed that echocardiography as a non-invasive method
can be very useful for this purpose.
3.3. Management of cirrhotic cardiomyopathy
No accepted pharmacologic treatment for cirrhotic cardio-
myopathy exists. To date, there are no clinical studies on the
management of cirrhotic cardiomyopathy. Once cardiac fail-
ure becomes evident following some forms of stress, manage-
ment should follow similar guidelines as in noncirrhotic
patients, although cardiac afterload reduction will not be well
tolerated in patients with advanced cirrhosis who aresigniﬁcantly vasodilated. Vasodilators, like ACE-inhibitors,
should be used very carefully because of the risk of further
aggravation of the systemic vasodilatory state [10]. The
treatment with diuretics is indicated in patients with water
retention. Aldosterone antagonists may have beneﬁcial
effects in the reduction of left ventricular dilatation, wall
thickness, and are potentially useful in the improvement of
diastolic function. It has been shown that β-adrenergic
blockade can lower portal pressure and potentially reduce
the degree of shunting of cardiotoxins from the splanchnic to
the systemic circulation. Zambruni and colleagues showed
beneﬁcial effect of chronic administration of β-blocker on QT
intervals in a cohort of cirrhotic patients with varying degrees
of decompensation [39].
New therapeutic approaches are under investigation.
Pozzi et al. demonstrated favorable effect of k-cancreolate
(aldosterone antagonist), which was able to reduce circula-
tory volume and to decrease left ventricular wall thickness
[40]. Similarly, agonists of farnesoid X receptor (a gene
involved in intrahepatic generation of vasodilator hydrogen
sulﬁde) and NCX-1000 (a new compound that releases NO in
the liver) are interesting new attempts aimed at correcting
the diminished production of endogenous hepatic vasodila-
tors during cirrhosis, but their usefulness is not yet clear in
cirrhotic cardiomyopathy [10,40].4. Conclusion
Liver cirrhosis is frequently associated with syndrome of
hyperdynamic circulation (increased cardiac output,
decreased peripheral systemic vascular resistance and nor-
mal or decreased arterial pressure). The recent evidence
indicates the presence of a subclinical myocardial disease
with increased myocardial ﬁbrosis and increased myocardial
mass. This can lead to increased stiffness of the myocardial
wall and can result in impaired ventricular ﬁlling and dia-
stolic dysfunction. It can progress into systolic dysfunction of
the left ventricle. These abnormalities are associated with
electrophysiological changes (QT interval prolongation).
The presence of the cardiomyopathy should be suspected
in patients with worsening hemodynamics. Such patients
may beneﬁt from more aggressive monitoring and treatment
of the underlying pathology leading to decompensation, and
close monitoring during procedures likely to cause decom-
pensation (i.e. TIPS, paracentesis, and liver transplant).
The management of cirrhotic cardiomyopathy, once iden-
tiﬁed, should follow the guidelines for the treatment of
patients with heart failure. No speciﬁc treatment or manage-
ment strategies have been tested for patients with cirrhotic
cardiomyopathy.Acknowledgments
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